Skip to main content
Historic redlining, modern neighborhood structures, and mortality in children, adolescents, and young adults with cancer.
Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.
Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.
Addition of chemo-immunotherapy to standard induction chemotherapy for high-risk neuroblastoma.
Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).
Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.
Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.
Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.
Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.